BMY vs. MRK, ABBV, PFE, ZTS, RPRX, JAZZ, PRGO, CORT, SUPN, and PCRX
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), and Pacira BioSciences (PCRX). These companies are all part of the "pharmaceuticals" industry.
Merck & Co., Inc. (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends.
Merck & Co., Inc. has a net margin of 3.76% compared to Merck & Co., Inc.'s net margin of -13.50%. Bristol-Myers Squibb's return on equity of 14.05% beat Merck & Co., Inc.'s return on equity.
76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are owned by institutional investors. 0.1% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Merck & Co., Inc. has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.
Bristol-Myers Squibb received 112 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. However, 66.97% of users gave Merck & Co., Inc. an outperform vote while only 66.89% of users gave Bristol-Myers Squibb an outperform vote.
Merck & Co., Inc. currently has a consensus price target of $131.33, indicating a potential upside of 4.61%. Bristol-Myers Squibb has a consensus price target of $60.00, indicating a potential upside of 46.02%. Given Merck & Co., Inc.'s higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Merck & Co., Inc..
Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.5%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 5.8%. Merck & Co., Inc. pays out 342.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Bristol-Myers Squibb pays out -77.4% of its earnings in the form of a dividend. Merck & Co., Inc. has raised its dividend for 13 consecutive years and Bristol-Myers Squibb has raised its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Bristol-Myers Squibb has lower revenue, but higher earnings than Merck & Co., Inc.. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.
In the previous week, Merck & Co., Inc. had 3 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 34 mentions for Merck & Co., Inc. and 31 mentions for Bristol-Myers Squibb. Merck & Co., Inc.'s average media sentiment score of 0.78 beat Bristol-Myers Squibb's score of 0.51 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.
Summary
Merck & Co., Inc. beats Bristol-Myers Squibb on 11 of the 20 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
